KANE WILLIAMSON will be available to lead New Zealand against India in the World Test Championship final, head coach Gary Stead announced on Tuesday (15) as he unveiled a 15-man squad for the match, starting June 18.
Williamson was forced to miss the second Test against England due to an elbow injury and in his absence Tom Latham led New Zealand to a comfortable eight-wicket win and also series triumph.
Wicketkeeper-batsman BJ Watling, who too had missed the second Test due to a back injury, has also been named in the squad.
"Kane and BJ have certainly benefitted from their week of rest and rehabilitation and we expect them to be fit and available for the final," Stead said at a press conference after the team's arrival at Southampton.
"Playing in a World Cup final is a really special occasion and I know the guys are looking forward to getting into their work here in Southampton," he added.
Stead said their victory over England notwithstanding, it is going to be a tough challenge facing India.
"India are a world class outfit who possess match winners all through their line-up, so we're under no illusion about how tough they will be to beat," he said.
New Zealand will go into the clash with one specialist spinner in 32-year-old left-arm spinner Ajaz Patel and allrounder Colin de Grandhomme
Will Young is their specialist batting cover, while Tom Blundell is the back-up wicket-keeper.
"We've gone with Ajaz as our specialist spinner after an impressive outing at Edgbaston and we believe he could be a factor at the Ageas Bowl," Stead said.
"Colin's been an integral member of our Test set-up for many years and it was great to see him return at Lord's after a long injury lay-off.
"He's a proven performer at the top level and we back him to do a job with the bat or the ball if called upon."
New Zealand have left out five players from their 20-man squad, including Doug Bracewell, Jacob Duffy, Daryl Mitchell, Rachin Ravindra and Mitchell Santner.
New Zealand squad:
Kane Williamson (C), Tom Blundell, Trent Boult, Devon Conway, Colin de Grandhomme, Matt Henry, Kyle Jamieson, Tom Latham, Henry Nicholls, Ajaz Patel, Tim Southee, Ross Taylor, Neil Wagner BJ Watling and Will Young.
UK life sciences sector contributed £17.6bn GVA in 2021 and supports 126,000 high-skilled jobs.
Inward life sciences FDI fell by 58 per cent from £1,897m in 2021 to £795m in 2023.
Experts warn NHS underinvestment and NICE pricing rules are deterring innovation and patient access.
Investment gap
Britain is seeking to attract new pharmaceutical investment as part of its plan to strengthen the life sciences sector, Chancellor Rachel Reeves said during meetings in Washington this week. “We do need to make sure that we are an attractive place for pharmaceuticals, and that includes on pricing, but in return for that, we want to see more investment flow to Britain,” Reeves told reporters.
Recent ABPI report, ‘Creating the conditions for investment and growth’, The UK’s pharmaceutical industry is integral to both the country’s health and growth missions, contributing £17.6 billion in direct gross value added (GVA) annually and supporting 126,000 high-skilled jobs across the nation. It also invests more in research and development (R&D) than any other sector. Yet inward life sciences foreign direct investment (FDI) fell by 58per cent, from £1,897 million in 2021 to £795 million in 2023, while pharmaceutical R&D investment in the UK lagged behind global growth trends, costing an estimated £1.3 billion in lost investment in 2023 alone.
Richard Torbett, ABPI Chief Executive, noted “The UK can lead globally in medicines and vaccines, unlocking billions in R&D investment and improving patient access but only if barriers are removed and innovation rewarded.”
The UK invests just 9% of healthcare spending in medicines, compared with 17% in Spain, and only 37% of new medicines are made fully available for their licensed indications, compared to 90% in Germany.
Expert reviews
Shailesh Solanki, executive editor of Pharmacy Business, pointed that “The government’s own review shows the sector is underfunded by about £2 billion per year. To make transformation a reality, this gap must be closed with clear plans for investment in people, premises and technology.”
The National Institute for Health and Care Excellence (NICE) cost-effectiveness threshold £20,000 to £30,000 per Quality-Adjusted Life Year (QALY) — has remained unchanged for over two decades, delaying or deterring new medicine launches. Raising it is viewed as vital to attracting foreign investment, expanding patient access, and maintaining the UK’s global standing in life sciences.
Guy Oliver, General Manager for Bristol Myers Squibb UK and Ireland, noted that " the current VPAG rate is leaving UK patients behind other countries, forcing cuts to NHS partnerships, clinical trials, and workforce despite government growth ambitions".
Reeves’ push for reform, supported by the ABPI’s Competitiveness Framework, underlines Britain’s intent to stay a leading hub for pharmaceutical innovation while ensuring NHS patients will gain faster access to new treatments.
By clicking the 'Subscribe’, you agree to receive our newsletter, marketing communications and industry
partners/sponsors sharing promotional product information via email and print communication from Garavi Gujarat
Publications Ltd and subsidiaries. You have the right to withdraw your consent at any time by clicking the
unsubscribe link in our emails. We will use your email address to personalize our communications and send you
relevant offers. Your data will be stored up to 30 days after unsubscribing.
Contact us at data@amg.biz to see how we manage and store your data.